Plant-Derived Compound Dicentrine Suppresses Lymphoma Cells in Preclinical Study
An alkaloid isolated from Stephania venosa halts cancer cell proliferation and triggers programmed cell death in vitro.
Key takeaways
- Dicentrine, an alkaloid from Stephania venosa, showed strong cytotoxic activity against Raji and Ramos human lymphoma cells.
- The compound achieved IC50 values of 9.03 ± 0.53 µg/mL in Raji cells and 5.16 ± 0.44 µg/mL in Ramos cells.
- Dicentrine demonstrated favorable selectivity toward lymphoma cells compared to peripheral blood mononuclear cells.
- The study identified AKT1 and the PI3K/Akt signaling pathway as key targets, with Western blots showing reduced total Akt protein expression.
- The treatment triggered cell cycle arrest (G0/G1 in Raji; G2/M in Ramos) and promoted apoptotic cell death.
A plant-derived compound known as dicentrine has demonstrated significant anti-cancer activity against human lymphoma cells in laboratory tests, according to a peer-reviewed study published in the International Journal of Molecular Sciences in August 2026.
Researchers evaluated the compound, which is an aporphine alkaloid isolated from the plant Stephania venosa, to identify potential new therapeutic agents for lymphoma. Lymphoma remains a major hematological malignancy that is frequently associated with treatment resistance and systemic toxicity. This clinical challenge highlights the ongoing need for novel anticancer agents derived from natural products.
In the laboratory study, dicentrine exhibited the strongest cytotoxic activity among the various isolated compounds tested against Raji and Ramos human lymphoma cell lines. It also demonstrated favorable selectivity toward these cancer cells when compared directly to peripheral blood mononuclear cells, suggesting a lower relative impact on healthy blood cells.
What Happened
Researchers analyzed the biological effects of the isolated aporphine alkaloid dicentrine on human lymphoma cell lines in a laboratory setting. The compound significantly reduced lymphoma cell proliferation and decreased total viable cell numbers in a dose-dependent manner.
To quantify its cell-killing potency, the study calculated the half-maximal inhibitory concentration (IC50) values. Dicentrine achieved an IC50 of 9.03 ± 0.53 µg/mL in Raji cells and 5.16 ± 0.44 µg/mL in Ramos cells.
Cell cycle analyses revealed that dicentrine halted cell replication at different phases depending on the specific lymphoma cell line: it caused G0/G1 arrest in Raji cells and G2/M arrest in Ramos cells. Furthermore, dicentrine successfully induced apoptosis, which was verified by an increased population of Annexin V-positive cells and elevated expression of cleaved caspase-3.
What The Evidence Shows
At the molecular level, the researchers found that dicentrine significantly suppressed both c-Myc and phosphorylated c-Myc expression.
To map out how the compound interacts with cellular machinery, molecular docking analyses were conducted. These computer simulations demonstrated that dicentrine has strong binding affinities toward several key proteins, specifically Akt, PI3K, caspase-3, and caspase-9.
Network pharmacology was then utilized to analyze these pathways, identifying the AKT1 protein and the broader PI3K/Akt signaling pathway as potential targets associated with lymphoma suppression. To validate these findings experimentally, the researchers performed a Western blot analysis. This laboratory test demonstrated that dicentrine significantly reduces total Akt protein expression in the treated human lymphoma cells.
What We Don't Know Yet
The published source does not report any animal model testing or human clinical trials, as this research was restricted to in vitro human cell-line experiments and in silico computer modeling. Because it is a preclinical, laboratory-based study, the safety, tolerability, and effectiveness of dicentrine in living organisms remain unknown. Furthermore, the overall sample size and the specific number of experimental replicates are not reported in the source text.
What Comes Next
The published source does not report what the researchers, sponsors, or clinical trials plan to do next. Whether this compound will enter animal models or transition to clinical evaluation in human subjects remains an open, unanswered question.
What This Means
These findings suggest that dicentrine suppresses lymphoma progression in cell lines by inhibiting cell proliferation and promoting apoptotic cell death. Its selective targeting of lymphoma cells and key molecular pathways like PI3K/Akt and c-Myc make it a promising natural therapeutic candidate. However, because these tests were restricted to cell lines, these results cannot be used to make clinical treatment decisions for patients.
Original Source
PubMed (NCBI E-utilities): https://pubmed.ncbi.nlm.nih.gov/42589628/
Questions readers ask
- What is dicentrine and where does it come from?
- Dicentrine is an aporphine alkaloid compound. It is isolated from the plant Stephania venosa.
- How does dicentrine affect human lymphoma cells in laboratory tests?
- In laboratory cell lines, dicentrine reduces cell proliferation, decreases the total number of viable cells, and induces apoptosis. It also halts cell cycle replication, causing G0/G1 arrest in Raji cells and G2/M arrest in Ramos cells.
- Which molecular pathways does dicentrine target to suppress lymphoma?
- Dicentrine significantly suppresses c-Myc and phosphorylated c-Myc expression and reduces total Akt protein expression. Molecular docking and network pharmacology identified Akt, PI3K, caspase-3, caspase-9, and the PI3K/Akt signaling pathway as potential targets.
What this means
These findings suggest that dicentrine suppresses lymphoma progression in cell lines by inhibiting cell proliferation and promoting apoptotic cell death. Its selective targeting of lymphoma cells and key molecular pathways like PI3K/Akt and c-Myc make it a promising natural therapeutic candidate. However, because these tests were restricted to cell lines, these results cannot be used to make clinical treatment decisions for patients.
Limitations and uncertainties
- The published source does not report any animal model testing or human clinical trials, as this research was restricted to in vitro human cell-line experiments and in silico computer modeling. Because it is a preclinical, laboratory-based study, the safety, tolerability, and effectiveness of dicentrine in living organisms remain unknown. Furthermore, the overall sample size and the specific number of experimental replicates are not reported in the source text.
Sources
- Molecular Pharmacological Characterization of Dicentrine Isolated from Stephania venosa in Human Lymphoma Cells. — PubMed (NCBI E-utilities)
